SEC Form 4
Skye Bioscience, Inc. (SKYE) insider trading
In the 12 months to Oct 26, 2026, 4 SKYE insiders reported open-market sales of $889.2K across 10 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $889.2K
- 10 filings · 4 insiders
- Open-market purchases
- $0
- 0 filings
Who traded SKYE, and when
- Sale
SKYE daily close from Oct 27, 2025 to Oct 26, 2026, between $1.53 and $12.88, last $1.55. 10 sale and 0 purchase filings by 4 insiders, marked at their filing dates. Andrew J. Schwab, Director: sold $444.6K across 3 filings, first filed Aug 20, 2026, last Sep 24, 2026. Kush Parmar, 10% owner: sold $312.4K across 2 filings, first filed Aug 20, 2026, last Sep 24, 2026. John D. Diekman, 10% owner: sold $85.9K across 3 filings, first filed Aug 20, 2026, last Sep 24, 2026. Scott M. Rocklage, 10% owner: sold $46.3K across 2 filings, first filed Aug 20, 2026, last Sep 24, 2026.
Largest mark · tap a row for others
Andrew J. Schwab · Director
Filing 1 of 2 within a week · $304,289 total
Sale $64,734
33,892 shares at $1.91 avg
Filed Sep 18, 2026 · traded Sep 16
Close on filing date $1.77
Andrew J. Schwab · Director
Director
$444.6K soldKush Parmar · 10% owner
10% owner
$312.4K soldJohn D. Diekman · 10% owner
10% owner
$85.9K soldScott M. Rocklage · 10% owner
10% owner
$46.3K soldOpen-market trades
10 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Andrew J. Schwab | Director | $444.6K | — | 3 | — | |
| Kush Parmar | 10% owner | $312.4K | — | 2 | — | |
| John D. Diekman | 10% owner | $85.9K | — | 3 | — | |
| Scott M. Rocklage | 10% owner | $46.3K | — | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | John D. Diekman 10% owner | Sale | 1,088 | $1.65 | $1.8K | 4,528 | |
traded | Kush Parmar 10% owner | Sale | 119,379 | $1.61 | $192.2K | Multiple accounts | |
traded | Scott M. Rocklage 10% owner | Sale | 27,612 | $1.65 | $45.6K | 114,851 | |
traded | Andrew J. Schwab Director | Sale | 148,079 | $1.62 | $239.6K | Multiple accounts | |
traded | John D. Diekman 10% owner | Sale | 33,892 | $1.91 | $64.7K | Multiple accounts | |
traded | Andrew J. Schwab Director | Sale | 33,892 | $1.91 | $64.7K | Multiple accounts | |
traded | Scott M. Rocklage 10% owner | Sale | 1,876 | $0.38 | $710 | 55,208 | |
traded | John D. Diekman 10% owner | Sale | 51,994 | $0.37 | $19.4K | Multiple accounts | |
traded | Kush Parmar 10% owner | Sale | 321,970 | $0.37 | $120.2K | Multiple accounts | |
traded | Andrew J. Schwab Director | Sale | 375,840 | $0.37 | $140.3K | Multiple accounts |
GET /stocks/filings/vX/form-4?tickers=SKYE&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"SKYE"
],
"issuer_cik": "0001516551",
"owner_cik": "0001390376",
"accession_number": "0001231919-26-001224",
"form_type": "4",
"filing_date": "2026-09-24",
"period_of_report": "2026-09-22",
"issuer_name": "Skye Bioscience, Inc.",
"issuer_trading_symbol": "SKYE",
"owner_name": "5AM CO-INVESTORS II LP",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-22",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 27612,
"transaction_price_per_share": 1.65,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 114851,
"transaction_value": 45559.799999999996,
"direct_or_indirect": "I",
"nature_of_ownership": "By 5AM Ventures II, L.P.",
"footnotes": [
{
"id": "F1",
"description": "The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."
}
]
},
{
"tickers": [
"SKYE"
],
"issuer_cik": "0001516551",
"owner_cik": "0001598549",
"accession_number": "0001598549-26-000015",
"form_type": "4",
"filing_date": "2026-09-24",
"period_of_report": "2026-09-22",
"issuer_name": "Skye Bioscience, Inc.",
"issuer_trading_symbol": "SKYE",
"owner_name": "Schwab Andrew J.",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-22",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 27612,
"transaction_price_per_share": 1.65,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 114851,
"transaction_value": 45559.799999999996,
"direct_or_indirect": "I",
"nature_of_ownership": "By 5AM Ventures II, L.P.",
"footnotes": [
{
"id": "F1",
"description": "The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 1 record
- Grants and awards1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Skye Bioscience, Inc.'s CEO sold stock?
No. Punit Dhillon (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is SKYE’s insider data?
These are SKYE Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track SKYE insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for SKYE every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.